[Clinical Value of Translocator Protein Gene in Evaluating the Efficacy of -ITD/ R882 Double-Mutated Acute Myeloid Leukemia].

Objective: To observe the clinical significance of translocator proteins (TSPO) gene in the treatment of -ITD/ R882 double-mutated acute myeloid leukemia (AML).

Methods: Seventy-six patients with AML hospitalized in the Department of Hematology of the Affiliated People's Hospital of Ningbo University from June 2018 to June 2020 were selected, including 34 patients with -ITD mutation, 27 patients with R882 mutation, 15 patients with -ITD/ R882 double mutation, as well as 19 patients with immune thrombocytopenia (ITP) hospitalized during the same period as control group. RNA was routinely extracted from 3 ml bone marrow retained during bone puncture, and gene expression was detected by transcriptome sequencing (using 2-deltadeltaCt calculation).

Results: The expression of gene in -ITD group and R882 group at first diagnosis was 2.02±1.04 and 1.85±0.76, respectively, which were both higher than 1.00±0.06 in control group, but the differences were not statistically significant (=0.671, =0.821). The expression of gene in the -ITD/ R882 group was 3.98±1.07, wich was significantly higher than that in the -ITD group and R882 group, the differences were statistically significant (=0.032, =0.021). The expression of gene in patients who achieved complete response after chemotherapy in the -ITD/ R882 group was 1.19±0.87, which was significantly lower than that at first diagnosis, and the difference was statistically significant (=0.011).

Conclusion: gene may be used as an indicator of efficacy in -ITD / R882 double-mutated AML.